[1]沈国华,周惠君,邓候富,等.68Ga标记的SSR靶向多肽PET/CT显像的研究进展及其在神经内分泌肿瘤中的初步应用[J].国际放射医学核医学杂志,2015,39(1):75-79.[doi:10.3760/cma.j.issn.1673-4114.2015.01.016]
 Shen Guohua,Zhou Huijun,Deng Houju,et al.Advances of 68Ga-labelled SSR-targeted peptides (DOTA-TOC,-TATE,-NOC) PET/CT imaging and its preliminary application in neuroendocrine tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):75-79.[doi:10.3760/cma.j.issn.1673-4114.2015.01.016]
点击复制

68Ga标记的SSR靶向多肽PET/CT显像的研究进展及其在神经内分泌肿瘤中的初步应用(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
39
期数:
2015年第1期
页码:
75-79
栏目:
出版日期:
2015-01-25

文章信息/Info

Title:
Advances of 68Ga-labelled SSR-targeted peptides (DOTA-TOC,-TATE,-NOC) PET/CT imaging and its preliminary application in neuroendocrine tumors
作者:
沈国华 周惠君 邓候富 贾志云
四川大学华西医院核医学科, 成都, 610041
Author(s):
Shen Guohua Zhou Huijun Deng Houju Jia Zhiyun
Department of Unclear Medicine, West China Hospitai, Sichuan University, Chengdu 610041, China
关键词:
正电子发射断层显像术体层摄影术X线计算机神经内分泌肿瘤68Ga-DOTA-TOC68Ga-DOTA-TATE68Ga-DOTA-NOC
Keywords:
Positron-emission tomographyTomography X-ray computedNeuroendocrine Tumors68Ga-DOTA-TOC68Ga-DOTA-TATE68Ga-DOTA-NOC
DOI:
10.3760/cma.j.issn.1673-4114.2015.01.016
摘要:
近年来,68Ga标记的多肽PET/CT显像为神经内分泌肿瘤(NET)的诊断提供了新的方法和视角。68Ge/68Ga发生器已经商业化,容易获得,并且68Ga标记过程简单方便,显像剂稳定性好。在此基础上,越来越多的研究比较了68Ga标记的多肽PET/CT与传统的形态学显像方法(CT、MRI)及生长抑素受体扫描对NET病灶的诊断效能,发现68Ga标记的多肽PET/CT远远优于后者。此外,68Ga标记的多肽PET/CT显像还能为患者治疗方案的选择、辐射剂量的调整甚至预后效果的评估提供多种重要信息,其有望成为NET患者肿瘤显像的临床首选。笔者就近年来68Ga标记的多肽PET/CT显像在临床上的初步应用研究作一综述。
Abstract:
In recent years, 68Ga-labelled peptides PET/CT has provided a new approach and perspective for the diagnosis of neuroendocrine tumors (NET). 68Ge/68Ga generator has been commercialized, with 68Ga obtained easily. The labeling process is easy, and the 68Ga-labelled peptides are stable.There are an increasing number of reports about the much better diagnostic performance of 68Ga-labelled peptides PET/CT for the detection of NET lesions as compared to traditional morphological imaging procedures (CT, MRI) and somatostatin receptor scintigraphy. In addition, it can offer important clinical information in selecting treatment plan, adjusting the radiation dose and assessing the prognosis. 68Ga-labelled peptides PET/CT is expected to be the standard method and first choice for imaging NET. An overview about the introduction and application of 68Ga-labelled peptides PET/CT in clinical practice is presented.

参考文献/References:

[1] Geijer H,Breimer LH.somatostatin receptor PET/CT in neuroen-docrine tumours:update on systematic review and meta-analysis[J].Eur J Nucl Med Mol Imaging,2013,40(11):1770-1780.
[2] Rufini V,Calcagni ML,Baum RP.Imaging of neuroendocrine tu-mors[J].Semin Nucl Med,2006,36(3):228-247.
[3] 王丽华,汪勇先,尹端祉.生长抑素及其类似物的标记技术的发展[J].核技术,2003,26(7):537-544.
[4] Roosenburg S,Laverman P,Joosten L,et al.PET and SPEC Tima-ging of a radiolabeled minigastrin analogue conjugated with DOTA.NOTA and NODAGA and labeled with 64Cu,68Ga and 111In[J].MolPharm,2014,11(11):3930-3937.
[5] Decristoforo C,Pickett RD,Verbruggen A.Feasibility and avai-lability of 68Ga-labelled peptides[J].Eur J Nucl Med Mol Imag-ing,2012,39 Suppl 1:S31-40.
[6] Zhernosekov KP,Filosofov DV,Baum RP,et al.Processing of gen-erator-produced 68Ga for medical application[J].J Nucl Med,2007,48(10):1741-1748.
[7] Hofmann M,Maecke H,Borner R,et al.Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC:preliminary data[J].Eur J Nucl Med,2001,28(12):1751-1757.
[8] Giesel FL,Stefanova M,Schwartz LH,et al.Impact of peptide re-ceptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue[J].Q J Nucl Med Mol Imaging,2013,57(2):171-176.
[9] Boy C,Heusner TA,Poeppel TD,et al.68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue:correlation of sst2 mRNA and SUVmax[J].Eur J Nucl Med Mol Imaging,2011,38(7):1224-1236.
[10] Gabriel M,Decristoforo C,Kendler D,et al.68Ga-DOTA-Tyr3-oc-treotide PET in neuroendocrine tumors:comparison with somato-statin receptor scintigraphy and CT[J].J Nucl Med,2007,48(4):508-518.
[11] Mayerhoefer ME,Schuetz M,Magnaldi S,et al.Are contrast media required for 68Ga-DOTATOC PET/CT in patients with neuroen-docrine tumours of the abdomen?[J].Eur Radiol,2012,22(4):938-946.
[12] Ezziddin S,Lohmar J,Yong-Hing CJ,et al.Does the pretherapeutic tumor SUV in 68Ga DO TATOC PET predict the absorbed dose of 177Lu octreotate?[J].Clin Nucl Med,2012,37(6):e141-e147.
[13] Kroiss A,Putzer D,Decristoforo C,et al.68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue:differentiation of physio-logical uptake and pathological processes in PET/CT[J].Eur J Nucl Med Mol Imaging,2013,40(4):514-523.
[14] Naswa N,Sharma P,Kumar R,et al.Usual and unusual neuroen-docrine tumor metastases on 68Ga-DOTANOC PET/CT:a pictorial review[J].Clin Nucl Med,2013,38(6):e239-e245.
[15] Fanti S,Ambrosini V,Tomassetti P,et al.Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET[J].Biomed Pharmacother,2008,62(10):667-671.
[16] Ambrosini V,Campana D,Tomassetti P,et al.68Ga-labelled pep-tides for diagnosis of gastroenteropancreatic NET[J].Eur J Nucl Med Mol Imaging,2012,39 Suppl 1:S52-60.
[17] Haug AR,Cindea-Drimus R,Auernhammer CJ,et al.The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors[J].J Nucl Med,2012,53(11):1686-1692.
[18] Hofman MS,Kong G,Neels OC,et al.High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours[J].J Med Imaging Radiat Oncol,2012,56(1):40-47.
[19] Demirci E,Ocak M,Kanasakal L,et al.Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours:preliminary results[J].Nucl Med Commun,2013,34(8):727-732.
[20] Kabasakal L,Demirci E,Ocak M,et al.Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same pa-tient group with neuroendocrine tumours[J].Eur J Nucl Med Mol Imaging,2012,39(8):1271-1277.
[21] Velikyan I,Sundin A,S?rensen J,et al.Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE:net uptake rate for accurate quantification[J].J Nucl Med,2014,55(2):204-210.
[22] Poeppel TD,Binse I,Petersenn S,et al.68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors[J].J Nucl Med,2011,52(12):1864-1870.
[23] Sandstr MM,Velikyan I,Garske-romn U,et al.Comparative biodis-tribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors[J].J Nucl Med,2013,54(10):1755-1759.
[24] Ruf J.Cost comparison of In-111-DTPA-octreotide scintigraphy and Ga-68-DOTATOC PET/CT in Germany:two sides of two different coins[J].Eur J Nucl Med Mol Imaging,2012,39(4):723-724.

相似文献/References:

[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
 He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
 Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[3]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
 Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[4]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
 Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[5]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
 Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[6]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
 Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[7]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
 Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[8]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
 Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[9]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
 Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[10]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
 Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[11]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
 Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[12]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
 Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[13]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
 You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[14]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
 Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[15]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
 Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[16]张巍,杨珂.18f正电子放射性药物生产及使用中医务人员的受照剂量研究[J].国际放射医学核医学杂志,2015,39(5):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
 zhang wei,yang ke..the research of radiation dose of 18f-fdg to pet/ct related personnel[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
[17]曹登敏,林美福,陈文新,等.继发性骨淋巴瘤的18F-FDG PET/CT影像学表现[J].国际放射医学核医学杂志,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
 Cao Dengmin,Lin Meifu,Chen Wenxin,et al.Analysis on 18F-FDG PET/CT imaging characteristics in secondary bone lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
[18]李生栩,唐明灯,林端瑜,等.18F-FDG PET/CT在胸段食管鳞癌淋巴结转移中的诊断价值[J].国际放射医学核医学杂志,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
 Li Shengxu,Tang Mingdeng,Lin Duanyu,et al.Value of 18F-FDG PET/CT in detecting metastatic lymph nodes of thoracic esophageal squamous cell carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
[19]张莹莹,王振光,武凤玉,等.特发性肺间质纤维化HRCT病变区与非病变区18F-FDG PET/CT表现分析[J].国际放射医学核医学杂志,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
 Zhang Yingying,Wang Zhenguang,Wu Fengyu,et al.18F-FDG PET/CT imaging analysis of regions with abnormal and normal pulmonary parenchyma on high resolution CT in idiopathic pulmonary fibrosis patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
[20]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
 Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]

备注/Memo

备注/Memo:
收稿日期:2014-10-28。
基金项目:国家自然科学基金(81171456;81271532/H1801)
通讯作者:贾志云,Email:shengh1990@126.com
更新日期/Last Update: 1900-01-01